BSEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioStem Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.54−0.55 (-26.32%)
Close on Oct 19, 2026
- Market cap
- $26.68M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | $7.90M | $-0.52 | – |
Company guidance
Outlook given with results on Aug 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | full year 2026 | $26.00M to $29.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements BioStem Technologies filed with the SEC
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BioStem Technologies Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
BioStem Technologies Announces Nasdaq Uplisting
Other events · EX-99.1 to Form 8-K